Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Sales | 3,994,687 | 4,010,144 | 3,820,320 | 4,161,368 | 3,960,322 |
| Cost of Goods | 573,588 | 571,904 | 587,298 | 675,143 | 609,828 |
| Gross Profit | 3,421,100 | 3,438,240 | 3,233,021 | 3,486,225 | 3,350,494 |
| Operating Expenses | 1,635,469 | 1,589,312 | 1,132,599 | 1,942,514 | 1,826,040 |
| Operating Income | 1,786,218 | 1,849,832 | 2,100,721 | 1,543,854 | 1,525,282 |
| Interest Expense | 276,282 | 252,977 | 251,201 | -62,264 | 78,498 |
| Other Income | 1,342 | -33,641 | 43,206 | -208,685 | 58,028 |
| Pre-tax Income | 1,511,278 | 1,563,214 | 1,892,726 | 1,397,433 | 1,504,812 |
| Income Tax | 261,372 | 326,781 | 395,524 | 304,702 | 347,812 |
| Net Income Continuous | 1,249,905 | 1,236,433 | 1,497,202 | 1,092,731 | 1,157,000 |
| Net Income | $1,249,905 | $1,236,433 | $1,497,202 | $1,092,731 | $1,157,000 |
| EPS Basic Total Ops | 0.24 | 0.24 | 0.29 | 0.21 | 0.22 |
| EPS Basic Continuous Ops | 0.24 | 0.24 | 0.29 | 0.21 | 0.22 |
| EPS Diluted Total Ops | 0.24 | 0.24 | 0.29 | 0.21 | 0.22 |
| EPS Diluted Continuous Ops | 0.24 | 0.24 | 0.29 | 0.21 | 0.22 |
| EBITDA(a) | $1,881,778 | $1,943,612 | $2,201,232 | $1,543,854 | $1,525,282 |